Results 81 to 90 of about 428 (116)

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms. [PDF]

Biomolecules
Al Musaimi O.
europepmc   +1 more source

Approaches used to model patient and carer health-related quality of life in economic models of rare disease treatments in NICE appraisals. [PDF]

Health Qual Life Outcomes
Wiedmann L, Cairns J.
europepmc   +1 more source

04111 Phlebotomy and afamelanotide as an efficient combined treatment of hepatoerythropoietic porphyria

Session 7 – New insights and potential treatment approaches in erythropoietic porphyrias (September 24th, 2024)
Luca Barbieri, Michele De Canio, Caterina Aurizi, Miriam Teoli   +3 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Afamelanotide: A Review in Erythropoietic Protoporphyria

American Journal of Clinical Dermatology, 2016
Afamelanotide (SCENESSE(®)) is a synthetic α-melanocyte stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist that is approved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is administered subcutaneously as a biodegradable, controlled-release implant containing 16 mg of ...
KARLY P Garnock-Jones, Esther S Kim, Kim Esther S   +2 more
exaly   +3 more sources

THE COST EFFECTIVENESS OF AFAMELANOTIDE FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORHYRIA [PDF]

Value in Health, 2016
J C Thompson
exaly   +2 more sources

Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria

Expert Review of Clinical Pharmacology, 2014
The application of afamelanotide, an α-melanocyte stimulating hormone agonistic analogue to protoporphyria, a disease with absolute sunlight-intolerance is discussed. The clinics, genetics and existing therapies of protoporphyria are described. The physiological receptor-mediated intracellular signaling of α-melanocyte stimulating hormone and effects ...
Elisabeth I, Minder, Xiaoye, Schneider-Yin   +1 more
openaire   +2 more sources

Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide

Nederlands Tijdschrift voor Tandheelkunde, 2020
The medicament afamelanotide is an analogue of endogenous ?-melanocyte-stimulating hormone. It promotes cutaneous pigmentation, providing protection from sunlight. In dermatology, afamelanotide seems to establish therapeutic results for polymorphic light eruption, solar urticaria, erythropoietic protoporphyria, Hailey-Hailey disease, vitiligo and acne ...
C, de Baat, K H, Phoa, P G M A, Zweers, M C, Bolling, F R, Rozema, A, Vissink   +5 more
openaire   +2 more sources

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria

British Journal of Dermatology, 2015
In erythropoietic protoporphyria (EPP), an inherited disease of porphyrin-biosynthesis, the accumulation of protoporphyrin in the skin causes severely painful phototoxic reactions. Symptom prevention was impossible until recently when afamelanotide became available.
G, Biolcati, E, Marchesini, F, Sorge, L, Barbieri, X, Schneider-Yin, E I, Minder   +5 more
exaly   +3 more sources